Policy Brief (Issue 9): Using Health Technology Assessment to address inefficient and unequal use of Nilotinib across Indonesia

It is vital to have evidence-informed clinical practice guidelines or clinical indications to guide the usage of high-cost drugs in the benefits package under the Indonesian universal health coverage (JKN), managed by BPJS Kesehatan.

A transparent and legit mechanism is required to support and monitor the prescription of drugs to ensure they are in line with available guidelines and indications. Without such mechanism in place, the costs to healthcare system can be significantly high, for example, this HTA study highlights the case of irrational use of Nilotinib can cost up to 0.5 million USD/year to BPJS.

There is a national uneven distribution of trained and technically sound human resources such as hemato-oncologists and clinicians.

For more information about this research: http://www.globalhitap.net/projects/idsi-indonesia/